What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “IB-001 is an investigational product targeting the type I IFN (IFN-I) signaling pathway. Subcutaneous (SC) injectable formulation; single doses in HVs (Part A) and weekly doses for 4 weeks in CHB participants (Part B). Exact dose levels recommended by SRC.”In the company’s words, NCT07389044 on ClinicalTrials.gov
- Tested for
- Chronic Hepatitis B Virus Infection
- Main trialPhase 1
- “This study will examine the safety and tolerability of single and multiple doses of IB-001 in two parts: Part A: SAD study in approximately 50 Healthy Volunteers (HV). Part B: MAD study in approximately 30 adult participants living with Chronic Hepatitis B (CHB). A separate exploratory, open-label, single-dose cohort (Part C) will evaluate pegylated interferon alfa-2a in HVs for translational benchmarking against IB-001.”In the company’s words, NCT07389044 on ClinicalTrials.gov
Other drugs for Chronic Hepatitis B Virus Infection
- GST-HG141Fujian Akeylink Biotechnology Co., Ltd. · Phase 3
- AHB-137Ausper Biopharma Co., Ltd. · Phase 3
- ZM-H1505RShanghai Zhimeng Biopharma, Inc. · Phase 3
- TQA3605Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Tenofovir DFGilead (Kite) · Phase 3
- HT-101Suzhou HepaThera Biotech Co., Ltd. · Phase 2
Coming up1
- 30 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Apr 2027 | A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026